ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Lupin seeks to pare new drug costs with string of licensing deals

Indian pharmaceutical firm seeks to control expenses amid slow US business

MUMBAI (NewsRise) -- Lupin is tying up a string of licensing deals with global pharmaceutical companies as the Indian drugmaker seeks to boost revenue and pare costs amid regulatory issues and a slow pace of pick up in new launches in the U.S.

On Wednesday, Lupin signed a deal with Germany's Boehringer Ingelheim to license, develop, and sell a new drug for patients suffering from difficult-to-treat cancers such as those affecting pancreas, colon, lungs, and skin. As part of the deal, Lupin will get an upfront payment of $20 million and an additional $700 million based on successfully achieving certain milestones, it said in a statement.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more